AR019241A1 - Derivados del acido hidroxi-pipecolato hidroxamico, composiciones que los contienen y procedimiento de tratamiento de artritis, cancer y otrasenfermedades. - Google Patents
Derivados del acido hidroxi-pipecolato hidroxamico, composiciones que los contienen y procedimiento de tratamiento de artritis, cancer y otrasenfermedades.Info
- Publication number
- AR019241A1 AR019241A1 ARP990103994A ARP990103994A AR019241A1 AR 019241 A1 AR019241 A1 AR 019241A1 AR P990103994 A ARP990103994 A AR P990103994A AR P990103994 A ARP990103994 A AR P990103994A AR 019241 A1 AR019241 A1 AR 019241A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- treatment
- hydroxamic
- arthritis
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Un compuesto de formula (I), en la que R1, R2, R3, R4, R5, R6, R7, R8, y Ar son como se ha definido en la memoria, util en el tratamiento deun trastorno seleccionado del grupo formado por artritis, cáncer y otras enfermedades caracterizadas por actividad de metaloproteinasas de la matrizo de reprolisina de mamífero. Además, los compuestos de la presente invencion se pueden usar en terapia de combinacion con fármacos antiinflamatoriosno esteroideos (AINE) convencionales, inhibidores de la COX-2 yanalgésicos y, en el tratamiento del cáncer, en combinacion con fármacos citotoxicoscomo adriamicina, daunomicina, cis-platino, etoposido, taxol, taxotero y otros alcaloides, como vincristina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9623298P | 1998-08-12 | 1998-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019241A1 true AR019241A1 (es) | 2001-12-26 |
Family
ID=22256467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103994A AR019241A1 (es) | 1998-08-12 | 1999-08-10 | Derivados del acido hidroxi-pipecolato hidroxamico, composiciones que los contienen y procedimiento de tratamiento de artritis, cancer y otrasenfermedades. |
Country Status (43)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| WO2000012093A1 (en) * | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Method of treating neurodegenerative diseases |
| US6509337B1 (en) * | 1998-09-17 | 2003-01-21 | Pfizer Inc. | Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
| EP1138680A1 (en) * | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| JP2001322977A (ja) * | 2000-05-12 | 2001-11-20 | Kotobuki Seiyaku Kk | ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物 |
| JP2002105073A (ja) * | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| BR0207209A (pt) | 2001-02-14 | 2004-01-27 | Warner Lambert Co | Inibidores de metaloproteinase de matriz de pirimidina |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| CA2462442A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| EP1516872A4 (en) * | 2002-06-26 | 2006-07-26 | Carna Biosciences Inc | NEW AZAZUCKER DERIVATIVE AND THIS MEDICAMENT CONTAINING ACTIVE SUBSTANCE |
| EP1534274A1 (en) * | 2002-07-17 | 2005-06-01 | Warner-Lambert Company LLC | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| BR0312666A (pt) * | 2002-07-17 | 2005-05-10 | Warner Lambert Co | Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib |
| WO2004014866A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| EP1537090A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| WO2004014908A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| EP1553949B1 (en) | 2002-08-13 | 2007-04-18 | Warner-Lambert Company LLC | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| CA2494014A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| WO2006131836A2 (en) * | 2005-03-22 | 2006-12-14 | Innodia Inc. | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| NZ587799A (en) | 2008-03-25 | 2012-06-29 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| PL2243772T3 (pl) | 2009-04-14 | 2012-05-31 | Affectis Pharmaceuticals Ag | Nowi antagoniści p2x7r i ich zastosowanie |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| DE202016007195U1 (de) | 2016-11-16 | 2017-11-17 | Bernhard Kohler | Strombegrenzende Schalteinrichtung |
| US20220008401A1 (en) * | 2019-01-29 | 2022-01-13 | Darsha Llc | Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| AU725831C (en) * | 1995-12-08 | 2002-10-17 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| RU2221782C2 (ru) * | 1996-08-28 | 2004-01-20 | Дзе Проктер Энд Гэмбл Компани | Замещенные циклические аминовые ингибиторы металлопротеаз |
| US6303636B1 (en) * | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| BR9807678A (pt) * | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| AU7294098A (en) * | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
-
1999
- 1999-05-08 UA UA2001010473A patent/UA59453C2/uk unknown
- 1999-07-30 PA PA19998479201A patent/PA8479201A1/es unknown
- 1999-08-03 YU YU5201A patent/YU5201A/sh unknown
- 1999-08-05 AP APAP/P/2001/002070A patent/AP2001002070A0/en unknown
- 1999-08-05 CA CA002340202A patent/CA2340202C/en not_active Expired - Fee Related
- 1999-08-05 SK SK187-2001A patent/SK1872001A3/sk unknown
- 1999-08-05 TR TR2001/00474T patent/TR200100474T2/xx unknown
- 1999-08-05 AU AU49247/99A patent/AU766366B2/en not_active Ceased
- 1999-08-05 AT AT99933076T patent/ATE325791T1/de not_active IP Right Cessation
- 1999-08-05 PL PL99346041A patent/PL346041A1/xx not_active Application Discontinuation
- 1999-08-05 CZ CZ2001484A patent/CZ2001484A3/cs unknown
- 1999-08-05 OA OA1200100035A patent/OA11594A/en unknown
- 1999-08-05 DE DE69931266T patent/DE69931266T2/de not_active Expired - Fee Related
- 1999-08-05 NZ NZ509296A patent/NZ509296A/en unknown
- 1999-08-05 EE EEP200100086A patent/EE200100086A/xx unknown
- 1999-08-05 CN CN99810697A patent/CN1316995A/zh active Pending
- 1999-08-05 EP EP99933076A patent/EP1104403B1/en not_active Expired - Lifetime
- 1999-08-05 ID IDW20010327A patent/ID27840A/id unknown
- 1999-08-05 ES ES99933076T patent/ES2263279T3/es not_active Expired - Lifetime
- 1999-08-05 HU HU0103452A patent/HUP0103452A3/hu unknown
- 1999-08-05 GE GEAP19995744A patent/GEP20033117B/en unknown
- 1999-08-05 EA EA200100126A patent/EA200100126A1/ru unknown
- 1999-08-05 BR BR9912909-4A patent/BR9912909A/pt not_active Application Discontinuation
- 1999-08-05 KR KR1020017001847A patent/KR20010085374A/ko not_active Application Discontinuation
- 1999-08-05 WO PCT/IB1999/001388 patent/WO2000009485A1/en active IP Right Grant
- 1999-08-05 JP JP2000564939A patent/JP2002522528A/ja not_active Ceased
- 1999-08-05 IL IL14103099A patent/IL141030A0/xx unknown
- 1999-08-09 HN HN1999000131A patent/HN1999000131A/es unknown
- 1999-08-10 PE PE1999000807A patent/PE20000951A1/es not_active Application Discontinuation
- 1999-08-10 AR ARP990103994A patent/AR019241A1/es not_active Application Discontinuation
- 1999-08-11 TN TNTNSN99156A patent/TNSN99156A1/fr unknown
- 1999-08-11 MA MA25730A patent/MA26675A1/fr unknown
- 1999-08-11 SV SV1999000123A patent/SV1999000123A/es not_active Application Discontinuation
- 1999-08-11 DZ DZ990170A patent/DZ2870A1/xx active
- 1999-08-12 US US09/372,946 patent/US6329397B1/en not_active Expired - Fee Related
- 1999-08-12 GT GT199900131A patent/GT199900131A/es unknown
-
2000
- 2000-01-28 UY UY25993A patent/UY25993A1/es unknown
-
2001
- 2001-01-16 IS IS5813A patent/IS5813A/is unknown
- 2001-02-07 ZA ZA200101042A patent/ZA200101042B/en unknown
- 2001-02-08 HR HR20010098A patent/HRP20010098A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010686A patent/NO20010686L/no not_active Application Discontinuation
- 2001-03-09 BG BG105323A patent/BG105323A/xx unknown
- 2001-12-03 US US10/008,943 patent/US20030008901A1/en not_active Abandoned
-
2002
- 2002-02-26 HK HK02101437.7A patent/HK1040242A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR019241A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico, composiciones que los contienen y procedimiento de tratamiento de artritis, cancer y otrasenfermedades. | |
| AR008260A1 (es) | Compuestos inhibidores de metaloproteasas matriciales basados en fosfinatos y composiciones farmaceuticas que los contienen | |
| BR0101241A (pt) | ácidos hidroxâmicos gem substituìdos | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| AR009292A1 (es) | Derivados del acido arilsulfonilamino hidroxamico, procesos para su preparacion y composiciones farmaceuticas que lo contienen | |
| GT200300177A (es) | Terapia de combinacion para enfermedades hiperproliferativas | |
| AR011056A1 (es) | Compuesto derivado de sulfona y composiciones farmaceuticas que los contiene | |
| YU37499A (sh) | Derivati arilsulfonil hidroksamske kiseline | |
| TR199901849T2 (xx) | Arils�lfonilamino hidroksamik asit t�revleri. | |
| UY25992A1 (es) | Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral) | |
| BRPI0413580A (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp | |
| BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
| UY26877A1 (es) | Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes | |
| AR026911A1 (es) | Preparado farmaceutica para el tratamiento de afecciones tumorales | |
| PT1181286E (pt) | Hidroxamidas de acido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxilico | |
| PA8471801A1 (es) | Derivados de higromicina a | |
| ES2160240T3 (es) | Benzamidas para el tratamiento de desordenes neurodegenerativos. | |
| ECSP993100A (es) | Derivados de acido hidroxi - pipecolato hidroxamico | |
| UY26741A1 (es) | Derivados de higromicina a | |
| ECSP993099A (es) | Inhibidores de tace | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP982358A (es) | Derivados ciclicos de sulfona | |
| ECSP972233A (es) | Derivados del acido arilsulfonilamino hidroxamico | |
| ECSP993239A (es) | Derivados de higromicina | |
| ECSP992943A (es) | Derivados de higromicina a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |